Li Kang Biomedical Co., Ltd. (6242.TWO)
TWD 43.9
(2.21%)
TWD 43.9
(2.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 96.74 Million | 157.24 Million | 60.44 Million | 81.66 Million | - |
| Net Income | 139.14 Million | 140.79 Million | 63.48 Million | 86.94 Million | - |
| Depreciation & Amortization | 11.74 Million | 10.98 Million | 12.89 Million | 15.01 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -19.69 Million | 18.76 Million | 3.07 Million | -4.43 Million | - |
| Other non-cash items | -4.45 Million | -2.16 Million | -1.83 Million | -640 Thousand | - |
| Investing Cash Flow | -61.84 Million | -59.61 Million | 12.2 Million | -73.07 Million | - |
| Investments in PPE | -3.26 Million | -2.69 Million | -4.44 Million | -1.88 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -64.19 Million | -60.53 Million | -33.06 Million | -72.14 Million | - |
| Sales/Maturities of investments | 2.18 Million | 2.2 Million | 47.5 Million | - | - |
| Other Investing Activities | 140 Thousand | -190 Thousand | - | -245 Thousand | 233 Thousand |
| Financing Cash Flow | -55.07 Million | -66.97 Million | -69.38 Million | -52.59 Million | - |
| Debt repayment | -35 Million | -33.47 Million | -7.51 Million | -8.19 Million | - |
| Dividends payments | -46.62 Million | -33.3 Million | -62.16 Million | -44.4 Million | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 22 Thousand | -197 Thousand | 288 Thousand | - | - |
| Accounts receivables | 916 Thousand | - | - | - | - |
| Accounts payables | -7.99 Million | - | - | - | - |
| Inventory | -8.79 Million | -4.25 Million | 2.64 Million | -2.11 Million | - |
| Other working capital | -11.81 Million | - | - | - | - |
| Cash at beginning of period | 132.01 Million | 101.35 Million | 98.09 Million | 142.1 Million | - |
| Cash at end of period | 111.84 Million | 132.01 Million | 101.35 Million | 98.09 Million | - |
| Capital Expenditure | -3.26 Million | -2.69 Million | -4.44 Million | -1.88 Million | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -20.17 Million | 30.65 Million | 3.25 Million | -44 Million | - |
| Free Cash Flow | 93.48 Million | 154.54 Million | 55.99 Million | 79.78 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 28.39 Million | 15.82 Million | 139.14 Million | 38.87 Million | 23.46 Million | 41.71 Million |
| Depreciation & Amortization | 3.35 Million | 3.53 Million | 11.74 Million | 3.45 Million | 3.06 Million | 2.45 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 4.64 Million | - | - | - | - |
| Change in working capital | 408 Thousand | -11.68 Million | -19.69 Million | 20.82 Million | -24.63 Million | -7.84 Million |
| Other non-cash items | -2.41 Million | -839 Thousand | -4.45 Million | -1.02 Million | -950 Thousand | -1.49 Million |
| Investing Cash Flow | -25.09 Million | -225.12 Million | -61.84 Million | -1.42 Million | -12.64 Million | -36.78 Million |
| Investments in PPE | -7.25 Million | -2.81 Million | -3.26 Million | -2.51 Million | -142 Thousand | 8000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -20.01 Million | -223.04 Million | -64.19 Million | 53 Thousand | -13.2 Million | -40.02 Million |
| Sales/Maturities of investments | - | - | 2.18 Million | - | - | - |
| Other Investing Activities | -19.04 Million | 56 Thousand | 140 Thousand | - | - | - |
| Financing Cash Flow | 35.17 Million | 225.26 Million | -55.07 Million | -11.73 Million | -43.36 Million | - |
| Debt repayment | -35 Million | - | -35 Million | -12 Million | -47 Million | - |
| Dividends payments | - | - | -46.62 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 225 Million | - | - | - | - |
| Other Financing Activities | 35 Million | - | 22 Thousand | - | - | - |
| Accounts receivables | -61 Thousand | - | - | - | - | - |
| Accounts payables | 10.62 Million | - | - | - | - | - |
| Inventory | -4.03 Million | -11.14 Million | -8.79 Million | 6.01 Million | -3.41 Million | -6.41 Million |
| Other working capital | -6.12 Million | - | - | - | - | - |
| Cash at beginning of period | 122.58 Million | 111.84 Million | 132.01 Million | 63.85 Million | 118.71 Million | 149.72 Million |
| Cash at end of period | 132.94 Million | 122.58 Million | 111.84 Million | 111.84 Million | 63.85 Million | 118.71 Million |
| Capital Expenditure | -7.25 Million | -2.81 Million | -3.26 Million | -2.51 Million | -142 Thousand | 8000.00 |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 10.35 Million | 10.74 Million | -20.17 Million | 47.98 Million | -54.85 Million | -31 Million |
| Free Cash Flow | -6.98 Million | 7.78 Million | 93.48 Million | 58.63 Million | 1 Million | 5.78 Million |
MTA
DZSI
FLO
ZBH
LPDNF
SANA